Compass Therapeutics, Inc.: management transactions · United States · SEC (Form 4)

About Compass Therapeutics, Inc.

Compass Therapeutics, Inc. (ticker: CMPX) is a clinical-stage biopharmaceutical company listed on the Nasdaq in the United States (United States), with headquarters in Boston, Massachusetts. The company focuses on oncology and is building a proprietary antibody-based platform designed to intervene at the intersection of angiogenesis, the immune system, and the tumor microenvironment. Its scientific premise is that anti-tumor activity can be improved by simultaneously targeting angiogenesis-driven pathways and immune-oncology mechanisms. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1738021/000117184325007005/cmpx20250930_10q.htm)) Compass was founded in 2014 and later became a public company through a reverse merger completed in 2020, giving it access to the public capital markets to fund clinical development. Since inception, management has devoted substantially all resources to research and development, intellectual property, staffing, and general corporate support. The company remains pre-commercial: it has not yet generated product revenue and continues to rely on equity financing and other capital sources to support operations. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1738021/000117184325002575/ars_042525.pdf)) The pipeline is centered on novel antibody assets, including CTX-471, a CD137 agonist antibody, CTX-8371, a PD-1 x PD-L1 bispecific antibody, and CTX-10726, a PD-1 x VEGF-A bispecific antibody. These programs are intended to enhance anti-tumor immune responses either as standalone agents or in combination regimens. From a competitive standpoint, Compass operates in a crowded and capital-intensive biotech landscape dominated by larger pharmaceutical and biotechnology groups, so differentiation depends heavily on clinical data, biomarker logic, and the ability to advance assets efficiently through development. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1738021/000117184325007005/cmpx20250930_10q.htm)) Geographically, the company is primarily U.S.-based, with its operational footprint anchored in Boston and clinical activity conducted through specialized research sites and collaborators. Recent developments have been encouraging but remain early-stage: in 2025, Compass reported that tovecimig met its primary endpoint in the randomized Phase 2/3 COMPANION-002 study in biliary tract cancer, while CTX-8371 showed confirmed partial responses in its Phase 1 program and expansion cohorts were opened or planned. Management also indicated plans to initiate a Phase 2 study for CTX-471 in 2026. Overall, CMPX offers investors a high-risk, data-driven oncology story with meaningful scientific optionality, but continued financing needs and regulatory uncertainty remain central to the investment case. ([investors.compasstherapeutics.com](https://investors.compasstherapeutics.com/news-releases/news-release-details/compass-therapeutics-reports-2025-second-quarter-financial?utm_source=openai))